NASDAQ: OCGN
Ocugen Inc Stock Forecast, Predictions & Price Target

Analyst price target for OCGN

Based on 1 analyst offering 12 month price targets for Ocugen Inc

Min Forecast
$7.00+382.76%
Avg Forecast
$7.00+382.76%
Max Forecast
$7.00+382.76%

Should I buy or sell OCGN stock?

Based on 1 analyst offering ratings for Ocugen Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although OCGN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates OCGN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their OCGN stock forecasts and price targets.

OCGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-20

1 of 1

Forecast return on equity

Is OCGN forecast to generate an efficient return?

Company
7,574.18%
Industry
352.12%
Market
211.34%
OCGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OCGN forecast to generate an efficient return on assets?

Company
464.61%
Industry
122.26%
OCGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OCGN earnings per share forecast

What is OCGN's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.25
Avg 2 year Forecast
-$0.04
Avg 3 year Forecast
$0.08

OCGN revenue forecast

What is OCGN's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$3.1M-41.49%
Avg 2 year Forecast
$133.2M+2,380.26%
Avg 3 year Forecast
$480.8M+8,853.45%
OCGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OCGN revenue growth forecast

How is OCGN forecast to perform vs Biotechnology companies and vs the US market?

Company
337.08%
Industry
116.92%
Market
23.08%
OCGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OCGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OCGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
OCGN$1.45$7.00+382.76%Strong Buy
ABSI$2.99$6.96+132.88%Strong Buy
PRTC$18.69N/AN/A
ADCT$3.61$8.50+135.46%Strong Buy
VNDA$7.54$13.63+80.70%Strong Buy

Ocugen Stock Forecast FAQ

Is Ocugen Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: OCGN) stock is to Strong Buy OCGN stock.

Out of 1 analyst, 1 (100%) are recommending OCGN as a Strong Buy, 0 (0%) are recommending OCGN as a Buy, 0 (0%) are recommending OCGN as a Hold, 0 (0%) are recommending OCGN as a Sell, and 0 (0%) are recommending OCGN as a Strong Sell.

If you're new to stock investing, here's how to buy Ocugen stock.

What is OCGN's earnings growth forecast for 2026-2028?

(NASDAQ: OCGN) Ocugen's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Ocugen's earnings in 2026 is -$64,022,000.On average, 7 Wall Street analysts forecast OCGN's earnings for 2026 to be -$77,080,604, with the lowest OCGN earnings forecast at -$88,761,376, and the highest OCGN earnings forecast at -$55,749,140. On average, 4 Wall Street analysts forecast OCGN's earnings for 2027 to be -$11,149,828, with the lowest OCGN earnings forecast at -$55,093,268, and the highest OCGN earnings forecast at $36,072,973.

In 2028, OCGN is forecast to generate $25,485,321 in earnings, with the lowest earnings forecast at $24,485,897 and the highest earnings forecast at $26,234,889.

What is OCGN's revenue growth forecast for 2026-2028?

(NASDAQ: OCGN) Ocugen's forecast annual revenue growth rate of 337.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Ocugen's revenue in 2026 is $5,370,000.On average, 7 Wall Street analysts forecast OCGN's revenue for 2026 to be $981,309,792, with the lowest OCGN revenue forecast at $0, and the highest OCGN revenue forecast at $1,967,616,706. On average, 4 Wall Street analysts forecast OCGN's revenue for 2027 to be $41,597,915,717, with the lowest OCGN revenue forecast at $31,103,959,954, and the highest OCGN revenue forecast at $52,319,865,162.

In 2028, OCGN is forecast to generate $150,163,509,850 in revenue, with the lowest revenue forecast at $93,330,619,069 and the highest revenue forecast at $202,680,136,682.

What is OCGN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: OCGN) forecast ROA is 464.61%, which is higher than the forecast US Biotechnology industry average of 122.26%.

What is OCGN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year OCGN price target, the average OCGN price target is $7.00, with the highest OCGN stock price forecast at $7.00 and the lowest OCGN stock price forecast at $7.00.

The Wall Street analyst predicted that Ocugen's share price could reach $7.00 by Jan 20, 2027. The average Ocugen stock price prediction forecasts a potential upside of 382.76% from the current OCGN share price of $1.45.

What is OCGN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: OCGN) Ocugen's current Earnings Per Share (EPS) is -$0.22. On average, analysts forecast that OCGN's EPS will be -$0.25 for 2026, with the lowest EPS forecast at -$0.28, and the highest EPS forecast at -$0.18. On average, analysts forecast that OCGN's EPS will be -$0.04 for 2027, with the lowest EPS forecast at -$0.18, and the highest EPS forecast at $0.12. In 2028, OCGN's EPS is forecast to hit $0.08 (min: $0.08, max: $0.08).

What is OCGN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: OCGN) forecast ROE is 7,574.18%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.